Taysha Gene Therapies (TSHA) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 1, 2026, with virtual attendance available for shareholders of record as of April 8, 2026.

• Proxy materials and annual report are accessible online, with options for paper or email copies upon request by May 18, 2026.

Voting matters and shareholder proposals

• Election of Class III Director nominees Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D., to serve until the 2029 annual meeting.

• Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025.

• Advisory vote to approve executive compensation for named executive officers.

• Advisory vote on the preferred frequency (recommended as annual) for future say-on-pay votes.

• Proxies may vote on other business arising at the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends the election of two director nominees for multi-year terms, reinforcing board continuity.